Somewhat Positive News Coverage Somewhat Unlikely to Impact BioTelemetry (BEAT) Stock Price

News stories about BioTelemetry (NASDAQ:BEAT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioTelemetry earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.607598186408 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of BioTelemetry (NASDAQ:BEAT) opened at $29.95 on Monday. The company has a market capitalization of $970.62, a price-to-earnings ratio of 41.03, a P/E/G ratio of 1.87 and a beta of 0.53. BioTelemetry has a 12 month low of $20.99 and a 12 month high of $39.20. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, November 7th. The medical research company reported $0.16 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.25 by ($0.09). The firm had revenue of $81.02 million for the quarter, compared to the consensus estimate of $82.10 million. BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. BioTelemetry’s revenue for the quarter was up 52.7% on a year-over-year basis. During the same quarter last year, the company posted $0.21 EPS. analysts expect that BioTelemetry will post 0.83 earnings per share for the current fiscal year.

BEAT has been the topic of several research analyst reports. Raymond James Financial initiated coverage on BioTelemetry in a research note on Thursday, October 26th. They set an “outperform” rating and a $37.00 price objective on the stock. Off Wall Street initiated coverage on BioTelemetry in a research note on Friday, September 15th. They set a “sell” rating on the stock. SunTrust Banks initiated coverage on BioTelemetry in a research note on Monday, October 23rd. They set a “buy” rating and a $41.00 price objective on the stock. Zacks Investment Research downgraded BioTelemetry from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 2nd. Finally, Dougherty & Co reaffirmed a “buy” rating and set a $40.00 price objective on shares of BioTelemetry in a research note on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $42.86.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact BioTelemetry (BEAT) Stock Price” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Insider Buying and Selling by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply